Rocket Pharmaceuticals Inc

NASDAQ:RCKT   3:59:54 PM EDT
22.79
-1.31 (-5.44%)
Products, Regulatory

Rocket Pharmaceuticals Announces Positive Updates From Phase 1 Clinical Trial Of Rp-A501 In Danon Disease

Published: 11/15/2021 12:24 GMT
Rocket Pharmaceuticals Inc (RCKT) - Rocket Pharmaceuticals Announces Positive Updates From Phase 1 Clinical Trial of Rp-a501 in Danon Disease.
Rocket Pharmaceuticals Inc - Rp-a501 Generally Well Tolerated at Low-dose With Manageable Safety Profile.
Rocket Pharmaceuticals - Sustained Improvement Or Stabilization in Bnp and 6-minute Walk Test Across Four Patients.
Rocket Pharma - Results Show Sustained Benefit Across Clinical, Functional and Biomarker Endpoints in All Four Patients With Long-term Follow Up.